TW200630083A - Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract - Google Patents

Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract

Info

Publication number
TW200630083A
TW200630083A TW094136193A TW94136193A TW200630083A TW 200630083 A TW200630083 A TW 200630083A TW 094136193 A TW094136193 A TW 094136193A TW 94136193 A TW94136193 A TW 94136193A TW 200630083 A TW200630083 A TW 200630083A
Authority
TW
Taiwan
Prior art keywords
disorders
prostate
treatment
beta
agonist
Prior art date
Application number
TW094136193A
Other languages
English (en)
Chinese (zh)
Inventor
Martin Michel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004050952A external-priority patent/DE102004050952A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW200630083A publication Critical patent/TW200630083A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW094136193A 2004-10-18 2005-10-17 Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract TW200630083A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004050952A DE102004050952A1 (de) 2004-10-18 2004-10-18 Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
US62459004P 2004-11-03 2004-11-03

Publications (1)

Publication Number Publication Date
TW200630083A true TW200630083A (en) 2006-09-01

Family

ID=36202691

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094136193A TW200630083A (en) 2004-10-18 2005-10-17 Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract

Country Status (6)

Country Link
US (1) US20060084700A1 (OSRAM)
EP (1) EP1804778A1 (OSRAM)
JP (1) JP2008516909A (OSRAM)
CA (1) CA2580170A1 (OSRAM)
TW (1) TW200630083A (OSRAM)
WO (1) WO2006042679A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
EP1955707A4 (en) * 2005-11-28 2010-09-01 Kissei Pharmaceutical PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROGENIC PAIN
EP2037927B1 (en) * 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
JP2010522751A (ja) * 2007-03-29 2010-07-08 メルク・シャープ・エンド・ドーム・コーポレイション 下部尿路症状の治療のための併用療法
CA2774992A1 (en) * 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
US8642661B2 (en) * 2010-08-03 2014-02-04 Altherx, Inc. Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
DE60229404D1 (de) * 2001-09-13 2008-11-27 Kissei Pharmaceutical Kristalle eines hydroxynorephedrinderivats
DE10251170A1 (de) * 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
EP1539181B1 (en) * 2003-04-04 2007-06-27 Dynogen Pharmaceuticals Inc. Method of treating lower urinary tract disorders
US20050222247A1 (en) * 2003-12-13 2005-10-06 Bayer Healthcare Ag Chroman derivatives

Also Published As

Publication number Publication date
CA2580170A1 (en) 2006-04-27
WO2006042679A1 (de) 2006-04-27
JP2008516909A (ja) 2008-05-22
EP1804778A1 (de) 2007-07-11
US20060084700A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
TNSN08147A1 (en) Pde inhibitors and combinations thereof for the treatment of urological disorders
TW200630083A (en) Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract
EP1887976B8 (en) Devices for treating benign prostatic hyperplasia and other conditions
WO2010065751A3 (en) Formulations of guanylate cyclase c agonists and methods of use
EP2026877A4 (en) Benign prostatic hyperplasia treatment device and method
WO2008019139A3 (en) Inhibitors of pyruvate kinase and methods of treating disease
WO2005053609A3 (en) Methods of nad+-dependent deacetylase inhibitors
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
CA2334460A1 (en) Pharmaceutical compositions comprising alpha-adrenoceptor antagonists and muscarinic antagonists
WO2007060471A3 (en) Biomarkers and methods for identification of agents useful in the treatment of affective disorders
WO2006018743A3 (en) Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder
WO2006102232A3 (en) Dosing regimes for trans-clomiphene
EP1959855A4 (en) TREATMENT OF BENIGNER PROSTATE HYPERPLASIA WITH A PHOTOSENSIBILIZER AND LASER ABLATION
NO20044333L (no) Farmasoytiske kombinasjon for behandling av godartet prostatis hyperplasi eller for langtidsprevensjon av akutt urinretensjon
UA56965U (ru) Средство для лечения и профилактики доброкачественной гиперплазии предстательной железы, простатита, импотенции, бесплодия и paka предстательной железы
WO2005117979A3 (en) Use of il-17 in the treatment of fertility-related disorders
FR2859910B1 (fr) Utilisation du 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27- bishomo-20-epi-cholecalciferol pour le traitement de l'hyperplasie benigne de la prostate
WO2006065968A8 (en) The uses of estrogen beta agonists to treat cognitive diseases
DK1427430T3 (da) Anvendelse af ekstrakter af cimicifuga-arter som organselektivt lægemiddel til behandling af seksualhormonafhængige sygdomme i urogenitalsystemet
EP2192903A4 (en) COMPOSITION AND METHOD OF TREATMENT OR METHOD PREVENTING SYMPTOMS BENIGNER PROSTATE HYPERPLASIA AND LOWER HARN
Parker Mixed methodological developments in UK-based dream research
WO2006102126A3 (en) Inhibitors of isoprenylcysteine carboxyl methyltransferase
Labrinakos Tradition regained: a study of Sir Richard Rodney Bennett's Partita (1995)
Hsu From smokers to addicts: a history of opium and its users in Taiwan